TY - JOUR
T1 - Lipid paradox in rheumatoid arthritis
T2 - Changes with rheumatoid arthritis therapies
AU - Urruela, Matxalen Amezaga
AU - Suarez-Almazor, Maria E.
N1 - Funding Information:
Acknowledgments Dr. Suarez-Almazor is the recipient of a K24 award from the National Institute on Arthritis, Musculoskeletal and Skin Disorders (NIAMS K24AR053593). The article’s contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAMS or NIH.
PY - 2012/10
Y1 - 2012/10
N2 - Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality, related not only to traditional CV risk factors, but also to a chronic inflammatory state. However, lipid profiles in RA are different from those observed in the general population at risk of CV disease, where there is evidence of a positive relationship between disease and high cholesterol levels. In untreated patients with active RA this relationship is different, with a paradoxical effect resulting in lower levels of cholesterol associated with an increased risk of CV disease. In this review, we summarize the latest evidence on lipid abnormalities in the setting of RA and the interaction between inflammation and lipoproteins, as well as the effect of DMARDs and biologic therapies on lipid profiles and the possible implications for CV outcomes in this population.
AB - Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality, related not only to traditional CV risk factors, but also to a chronic inflammatory state. However, lipid profiles in RA are different from those observed in the general population at risk of CV disease, where there is evidence of a positive relationship between disease and high cholesterol levels. In untreated patients with active RA this relationship is different, with a paradoxical effect resulting in lower levels of cholesterol associated with an increased risk of CV disease. In this review, we summarize the latest evidence on lipid abnormalities in the setting of RA and the interaction between inflammation and lipoproteins, as well as the effect of DMARDs and biologic therapies on lipid profiles and the possible implications for CV outcomes in this population.
KW - Atherosclerosis
KW - Cardiovascular risk
KW - Lipid profile
KW - Lipids
KW - Markers of inflammation
KW - Paradox
KW - Rheumatoid arthritis
KW - Risk factors
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84869153058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869153058&partnerID=8YFLogxK
U2 - 10.1007/s11926-012-0269-z
DO - 10.1007/s11926-012-0269-z
M3 - Review article
C2 - 22802154
AN - SCOPUS:84869153058
SN - 1523-3774
VL - 14
SP - 428
EP - 437
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 5
ER -